Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10374	Companies
216189	Keywords
145888	Articles
114464	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 08/19/2025 at 15:00, 8 months 22 days ago

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals plans FDA meeting to discuss crofelemer clinical program for MVID, with proof-of-concept results reducing TPN. Abstract accepted for NASPGHAN 2025 Annual Meeting in Chicago

Napo Pharmaceuticals Crofelemer MVID FDA Meeting NASPGHAN 2025 Annual Meeting
BRIEF

published on 08/14/2025 at 14:05, 8 months 27 days ago

Croissance financière et projets futurs de Jaguar Health au deuxième trimestre 2025

Stratégie Financière Jaguar Health Croissance De Mytesi Chiffre D'affaires Du Deuxième Trimestre 2025 Recherche Sur Crofelemer
BRIEF

published on 08/14/2025 at 14:05, 8 months 27 days ago

Jaguar Health's Q2 2025 Financial Growth and Future Plans

Jaguar Health Financial Strategy Q2 2025 Revenue Mytesi Growth Crofelemer Research
PRESS RELEASE

published on 08/14/2025 at 14:00, 8 months 27 days ago

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue
Jaguar Health, Inc. reports 35% revenue increase in Q2 2025 for prescription & non-prescription products, including license revenue. Mytesi prescription volume up 6.5%. Crofelemer trial yields positive results

Jaguar Health Inc. FDA Meeting Crofelemer Trial Q2 2025 Revenue Mytesi Prescription Volume
BRIEF

published on 08/12/2025 at 15:05, 8 months 29 days ago

Jaguar Health annonce un webcast destiné aux investisseurs le 14 août 2025

Résultats Financiers Jaguar Health Lisa Conte Médicaments Webcast Pour Les Investisseurs
BRIEF

published on 08/12/2025 at 15:05, 8 months 29 days ago

Jaguar Health Announces Investor Webcast on August 14, 2025

Financial Results Pharmaceuticals Investor Webcast Jaguar Health Lisa Conte
PRESS RELEASE

published on 08/12/2025 at 15:00, 8 months 29 days ago

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates
Jaguar Health, Inc. to conduct investor webcast on August 14, 2025 to review Q2 financials and corporate updates. CEO Lisa Conte presenting at Emerging Growth Conference on August 20, 2025

Investor Webcast Lisa Conte Emerging Growth Conference Jaguar Health Inc. Q2 Financials
BRIEF

published on 07/10/2025 at 14:35, 10 months ago

Jaguar Health étend son étude sur Canalevia-CA1 pour chiens

Jaguar Health Canalevia-CA1 Santé Animale Approbation De La FDA Diarrhée Du Chien
BRIEF

published on 07/10/2025 at 14:35, 10 months ago

Jaguar Health Expands Study on Canalevia-CA1 for Dogs

FDA Approval Jaguar Health Canalevia-CA1 Animal Health Dog Diarrhea
PRESS RELEASE

published on 07/10/2025 at 14:30, 10 months ago

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Jaguar Health, Inc. in talks with animal health partners to bring Canalevia to global market for general diarrhea in dogs. CEO presents at conference to discuss updates on Canalevia-CA1

Jaguar Health Conference Canalevia Animal Health Partners General Diarrhea

Accesswire

Published on 05/09/2026 at 01:55, 1 day 17 hours ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 1 day 17 hours ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 1 day 17 hours ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 19 hours ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 1 day 20 hours ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/10/2026 at 16:05, 3 hours 15 minutes ago

RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 5 hours 20 minutes ago

MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 7 hours 35 minutes ago

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 1 day ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 22 hours ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations

Les Echos

Published on 05/07/2026 at 19:15, 3 days ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE